Apogee Therapeutics to Participate in Upcoming June Conferences
Apogee Therapeutics (Nasdaq: APGE) announced management participation in two June 2026 investor conferences.
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE) announced management participation in two June 2026 investor conferences.
The company will join the Jefferies Global Healthcare Conference on June 3, 2026 at 11:40 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026 at 9:20 a.m. ET. Live and archived webcasts will be accessible on Apogee's investor website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – APGE
In the May 29 session, APGE gained 5.55%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Jefferies conference date
- June 3, 2026
- Jefferies Global Healthcare Conference participation date
- Jefferies fireside time
- 11:40 a.m. ET
- Scheduled fireside chat time at Jefferies conference
- Goldman Sachs conference date
- June 10, 2026
- Goldman Sachs 47th Annual Global Healthcare Conference date
- Goldman Sachs fireside time
- 9:20 a.m. ET
- Scheduled fireside chat time at Goldman Sachs conference
Historical Context
-
Up to $1.3B Blackstone collaboration to fund Phase 3 and commercialization.
-
Phase 2 APEX trial met all endpoints; mid-dose advancing to Phase 3.
-
Planned call to present 16-week Part B data from APEX trial.
-
Q1 2026 update with $1.3B cash and supportive Phase 2 data.
-
Public equity raise of $403M at $70 per share using shelf.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.
Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Time: 11:40 a.m. ET
Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Time: 9:20 a.m. ET
A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.